Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings

Benabdessalem, Chaouki; Hamouda, Wafa Ben; Marzouki, Soumaya; Faye, Rokhaya; Mbow, Adji Astou; Diouf, Babacar; Ndiaye, Oumar; Dia, Ndongo; Faye, Ousmane; Sall, Amadou Alpha; Diagne, Cheikh Tidiane; Amellal, Houda; Ezzikouri, Sayeh; Mioramalala, Diary Juliannie Ny; Randrianarisaona, Fanirisoa; Trabelsi, Khaled; Boumaiza, Mohamed; Hamouda, S.; Ouni, Rym; Bchiri, Soumaya; Chaaban, Amani; Gdoura, Mariem; Gorgi, Yousr; Sfar, Imen; Yalaoui, Sadok; Khelil, Jalila Ben; Hamzaoui, A.; Abdallah, M.; Cherif, Yosra; Pêtres, Stéphane; Mok, Chris Ka Pun; Escriou, Nicolas; Quesney, Sébastien; Dellagi, Koussay; Schoenhals, Matthieu; Sarih, M’hammed; Vigan-Womas, Inès; Bettaieb, Jihéne; Rourou, Samia; Barbouche, Mohamed Ridha; Ahmed, Mélika Ben

doi:10.1016/j.diagmicrobio.2023.115903

Cited by 8 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential for ecological fallacy plus the high between-dataset heterogeneity should add extra caution to the interpretation of the results of the presented meta-analyses. Nevertheless, the more limited individual sample level data available also agree with the main findings regarding malaria [30] and HIV. Third, some analyses include datasets that represent the same samples tested with different assays, therefore they are not entirely independent.…”

Section: Discussionsupporting

confidence: 77%

Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis

Ioannidis

Contopoulos‐Ioannidis

2023

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis

Ioannidis

Contopoulos‐Ioannidis

2023

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…This ELISA was developed in Tunisia and its performance was tested in different African settings with variable endemicity. In fact, we participated in the evaluation and validation of this in-house ELISA [ 34 ]. The sensitivity of the anti-N IgG ELISA test was 92% and specificity 94%.…”

Section: Methodsmentioning

confidence: 99%

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Coronavirus 2019 (COVID-19) is a global health threat. The kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be assessed, as the long-term duration of these immunoglobulins remains largely controversial. The aim of this study was to assess the longitudinal dynamics of anti-SARS-CoV-2 antibodies against the nucleocapsid (N) protein and the receptor-binding domain (RBD) of the spike protein up to one year in a cohort of 190 COVID-19 patients. Between March and September 2021, we enrolled patients from two regional hospitals in Casablanca, Morocco. Blood samples were collected and analyzed for antibody levels. We used the commercial Euroimmun ELISA for the determination of anti-N IgM, the Abbott Architect™ SARS-CoV-2 IgG test for the detection of anti-RBD IgG, and an in-house kit for the assay of anti-N IgG and anti-N IgA. IgM and IgA antibodies were assessed 2–5, 9–12, 17–20 and 32–37 days after symptom onset. IgG antibodies were also assessed 60, 90, 120 and 360 days after symptom onset. One-third of patients developed IgM (32%), while two-thirds developed IgA (61%). One month of symptom onset, most patients developed IgG, with 97% and 93% positivity for anti-RBD IgG and anti-N IgG, respectively. The anti-RBD IgG positivity rate remained high up to one year of follow-up. However, the anti-N IgG positivity rate decreased over time, with only 41% of patients testing positive after one year’s follow-up. IgG levels were significantly higher in older people (over 50 years) than in other study participants. We also found that patients who had received two doses of ChAdOx1 nCoV-19 vaccine prior to infection had a lower IgM response than unvaccinated patients. This difference was statistically significant two weeks after the onset of symptoms. We present the first study in Africa to measure the kinetics of antibody response (IgA, IgM and IgG) to SARS-CoV-2 over one year. Most participants remained seropositive for anti-RBD IgG after one year but showed a significant decline in antibody titers.

show abstract

“…In order to detect SARS-CoV-2 exposure in the study participants, we combined two sources of information: the positive results of RT-PCR testing for SARS-CoV-2 [ 30 ] and/or detection of antibodies to the N protein by in-house ELISA test [ 31 ], prior to inclusion in the cohort or during the post-vaccination follow-up. Of note, for inactivated vaccine recipients, only positive PCRs for SARS-CoV-2 were considered.…”

Section: Methodsmentioning

confidence: 99%

“…We optimized the entire upstream and downstream process for the production of the RBD spike S1 protein of SARS-CoV-2 (Wuhan-hu-1 strain) using Sf9 insect cells/baculovirus vector expression system (BEVS) in order to develop an ELISA assay [ 32 ]. The developed ELISA to detect S-RBD-specific IgG antibodies was validated and cross-validated in various endemic African settings [ 31 ]. Briefly, serum samples were diluted at 1:400 in PBS-0.01% Tween 20 (PBS-T), and then incubated in ELISA plates (Maxisorp Nunc, Thermo Fisher Scientific, Massachusetts, MA, USA) coated with recombinant SARS-CoV-2 S–RBD protein (2 µg/mL, 50 µL/well).…”

Section: Methodsmentioning

confidence: 99%

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms

Ben Hamouda,

Hanachi,

Ben Hamouda

et al. 2024

TropicalMed

Self Cite

View full text Add to dashboard Cite

Background: Vaccination constitutes the best strategy against COVID-19. In Tunisia, seven vaccines standing for the three main platforms, namely RNA, viral vector, and inactivated vaccines, have been used to vaccinate the population at a large scale. This study aimed to assess, in our setting, the kinetics of vaccine-induced anti-RBD IgG and IgA antibody responses. Methods: Using in-house developed and validated ELISA assays, we measured anti-RBD IgG and IgA serum antibodies in 186 vaccinated workers at the Institut Pasteur de Tunis over 12 months. Results: We showed that RNA vaccines were the most immunogenic vaccines, as compared to alum-adjuvanted inactivated and viral-vector vaccines, either in SARS-CoV-2-naïve or in SARS-CoV-2-experienced individuals. In addition to the IgG antibodies, the vaccination elicited RBD-specific IgAs. Vaccinated individuals with prior SARS-CoV-2 infection exhibited more robust IgG and IgA antibody responses, as compared to SARS-CoV-2-naïve individuals. Conclusions: After following up for 12 months post-immunization, we concluded that the hierarchy between the platforms for anti-RBD antibody-titer dynamics was RNA vaccines, followed by viral-vector and alum-adjuvanted inactivated vaccines.

show abstract

Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings

Cited by 8 publications

References 30 publications

Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis

Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms

Contact Info

Product

Resources

About